May 10, 2007 (Las Vegas) — Rituximab can be safely infused using a rapid 90-minute protocol in patients with non-Hodgkin's lymphoma, according to a presentation made at the annual meeting of the ...

Medicare Part B (medical insurance) may cover Rituxan (rituximab) infusions. This is because medical professionals typically administer the medication in a medical setting on an outpatient basis.Does ...

THOUSAND OAKS, Calif., June 6, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® ...

Serious infusion-related reactions can happen during your infusion or within 24 hours after your infusion of Rituxan. Your healthcare provider should give you medicines before your infusion of Rituxan ...

The combination of Calquence and Rituxan may also be useful during the COVID-19 pandemic as it decreases infusion times and patient interactions, according to an expert. Calquence (acalabrutinib) and ...

A study examining the relation between rituximab infusion and hospitalization as a result of COVID-19 for patients with multiple sclerosis (MS) found that the 2 were not related, contradicting past ...

Please provide your email address to receive an email when new articles are posted on . The timing of rituximab infusion or cumulative lifetime rituximab dose did not appear statistically ...

(HealthDay)—Rituxan (rituximab) injection was granted the first approval for a drug to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in combination with ...

Longitudinal study of anti-myeloma treatment patterns in a U.S. commercial population before and after approval of bortezomib (BOR). The utility and prognostic value of positron emission tomography ...

Rituxan Phase II Data Presented at the American Academy of Neruology Rituxan Significantly Reduced Signs Of Disease Activity As Measured By MRI and Relapse BOSTON- May 1, 2007 - Genentech and Biogen ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the ...

—Rituxan is the first and only FDA-approved treatment for pediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis— “Rituxan is now approved ...